Mauna Kea Technologies 将来の成長

Future 基準チェック /16

Mauna Kea Technologiesは、14.3%と8%でそれぞれ年率14.3%で利益と収益が成長すると予測される一方、EPSはgrowで12.7%年率。

主要情報

14.3%

収益成長率

12.7%

EPS成長率

Medical Equipment 収益成長	14.9%
収益成長率	8.0%
将来の株主資本利益率	n/a
アナリストカバレッジ	Low
最終更新日	05 Sep 2024

今後の成長に関する最新情報

Recent updates

What Mauna Kea Technologies SA's (EPA:ALMKT) 31% Share Price Gain Is Not Telling You

Jul 23

Mauna Kea Technologies SA's (EPA:ALMKT) Share Price Could Signal Some Risk

Mar 23

What Is Mauna Kea Technologies SA's (EPA:MKEA) Share Price Doing?

Jan 12

Mauna Kea Technologies (EPA:MKEA) Share Prices Have Dropped 70% In The Last Three Years

Nov 26

業績と収益の成長予測

ENXTPA:ALMKT - アナリストの将来予測と過去の財務データ ( )EUR Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
12/31/2026	9	-8	-7	-6	1
12/31/2025	8	-8	-8	-7	1
12/31/2024	7	-9	-15	-8	1
6/30/2024	8	-11	-8	-7	N/A
3/31/2024	10	-7	-4	-4	N/A
12/31/2023	11	-4	-1	-1	N/A
9/30/2023	11	-3	-1	0	N/A
6/30/2023	12	-2	0	0	N/A
3/31/2023	10	-7	-4	-4	N/A
12/31/2022	8	-11	-9	-9	N/A
9/30/2022	8	-12	-10	-10	N/A
6/30/2022	8	-13	-11	-11	N/A
3/31/2022	8	-13	-11	-11	N/A
12/31/2021	9	-13	-11	-10	N/A
9/30/2021	8	-13	-11	-10	N/A
6/30/2021	8	-13	-11	-10	N/A
3/31/2021	8	-13	-10	-9	N/A
12/31/2020	7	-13	-9	-8	N/A
9/30/2020	7	-13	-10	-9	N/A
6/30/2020	7	-14	-12	-10	N/A
3/31/2020	8	-15	-12	-10	N/A
12/31/2019	9	-15	-12	-10	N/A
9/30/2019	9	-15	-11	-10	N/A
6/30/2019	9	-14	-11	-9	N/A
3/31/2019	9	-13	-12	-10	N/A
12/31/2018	8	-13	-12	-11	N/A
9/30/2018	8	-12	-11	-11	N/A
6/30/2018	7	-11	-11	-10	N/A
3/31/2018	8	-11	N/A	-10	N/A
12/31/2017	8	-10	N/A	-10	N/A
9/30/2017	8	-10	N/A	-9	N/A
6/30/2017	8	-11	N/A	-9	N/A
3/31/2017	9	-10	N/A	-8	N/A
12/31/2016	10	-10	N/A	-8	N/A
9/30/2016	10	-10	N/A	-8	N/A
6/30/2016	10	-10	N/A	-8	N/A
3/31/2016	10	-11	N/A	-10	N/A
12/31/2015	10	-13	N/A	-12	N/A
9/30/2015	11	-13	N/A	-12	N/A
6/30/2015	12	-14	N/A	-13	N/A
3/31/2015	12	-14	N/A	-13	N/A
12/31/2014	12	-14	N/A	-13	N/A
9/30/2014	12	-13	N/A	-12	N/A
6/30/2014	11	-12	N/A	-11	N/A
3/31/2014	11	-12	N/A	-10	N/A
12/31/2013	11	-12	N/A	-10	N/A

アナリストによる今後の成長予測

収入対貯蓄率: ALMKT今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: ALMKT今後 3 年間、利益が出ない状態が続くと予測されています。

高成長収益: ALMKT今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: ALMKTの収益 ( 8% ) French市場 ( 5.6% ) よりも速いペースで成長すると予測されています。

高い収益成長: ALMKTの収益 ( 8% ) 20%よりも低い成長が予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: ALMKTの自己資本利益率が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です

Mauna Kea Technologies 将来の成長

Future 基準チェック /16

主要情報

今後の成長に関する最新情報

Mauna Kea Technologies Sa Reaffirms Sales Guidance for the Year 2024

Consensus EPS estimates fall by 13%

Mauna Kea Technologies SA Provides Sales Guidance for the Year 2024

No longer forecast to breakeven

No longer forecast to breakeven

Consensus revenue estimates fall by 15%

Recent updates

Mauna Kea Technologies Announces New Positive Clinical Results for Cellvizio in Food Intolerance

First half 2024 earnings released

Mauna Kea Technologies Sa Reaffirms Sales Guidance for the Year 2024

Mauna Kea Technologies Announces Positive Clinical Results in Lung Cancer Obtains with Cellvizio

New major risk - Share price stability

Mauna Kea Technologies SA to Report First Half, 2024 Results on Oct 30, 2024

What Mauna Kea Technologies SA's (EPA:ALMKT) 31% Share Price Gain Is Not Telling You

New minor risk - Share price stability

New minor risk - Share price stability

Mauna Kea Technologies SA to Report First Half, 2024 Results on Oct 02, 2024

Consensus EPS estimates fall by 13%

New major risk - Negative shareholders equity

Mauna Kea Technologies SA Provides Sales Guidance for the Year 2024

New minor risk - Financial data availability

New minor risk - Share price stability

Mauna Kea Technologies SA's (EPA:ALMKT) Share Price Could Signal Some Risk

New minor risk - Share price stability

Mauna Kea Technologies SA, Annual General Meeting, Jun 06, 2024

Insufficient new directors

Mauna Kea Technologies SA ADR - Sponsored to Be Deleted from OTC Equity

Mauna Kea Technologies SA announced that it expects to receive €6 million in funding from Telix Pharmaceuticals Limited

New minor risk - Share price stability

Mauna Kea Technologies Announces First Patient Enrolled in the Pivotal CLEVER Clinical Trial in Peripheral Lung Cancer

No longer forecast to breakeven

First half 2023 earnings released: EPS: €0.063 (vs €0.14 loss in 1H 2022)

New major risk - Revenue and earnings growth

Mauna Kea Technologies and Endoscopy Institute of Hawaii Achieve 1,200 Procedure Milestone

No longer forecast to breakeven

Mauna Kea Technologies Appoints Côme de La Tour du Pin as its Chief Financial Officer

Mauna Kea Technologies Announces Start of Enrollment in Peripheral Lung Cancer Multi-Site Clinical Trial Combining Ion® with Cellvizio®

Consensus revenue estimates fall by 15%

Mauna Kea Technologies SA to Report First Half, 2023 Results on Sep 28, 2023

Mauna Kea Technologies SA Announces the Publication of Results of the First in Human Clinical Study Combining Robotic-Assisted Bronchoscopy and Needle-Based Confocal Laser Endomicroscopy for Lung Cancer

No longer forecast to breakeven

Mauna Kea Technologies SA Announces Success of Clinical Trial on Prediction of Remission in Patients with Inflammatory Bowel Disease (IBD) and its Publication in Gastroenterology

Mauna Kea Technologies SA Announces the Appointment of Sacha Loiseau as Chief Executive Officer

Mauna Kea Technologies SA to Report First Half, 2022 Final Results on Oct 20, 2022

Mauna Kea Technologies SA to Report First Half, 2022 Results on Oct 20, 2022

Consensus forecasts updated

Price target decreased to €1.45

No longer forecast to breakeven

No longer forecast to breakeven

Mauna Kea Technologies Announces First of Its Kind U.S. FDA 510(k) Clearance for Use of Cellvizio in a New Category of Molecular Imaging-guided Endoscopic, Laparoscopic, Needle-Based Procedures

Mauna Kea Technologies SA Announces Start of Enrollment in Peripheral Lung Cancer Multi-Center Clinical Trial

Mauna Kea Technologies SA announced that it has received $12.8 million in funding from Lightspeed China Partners, Qiming Weichuang Venture Capital Management (Shanghai) Company Limited, Shanghai Ivy Investment Holdings Co., Ltd.

First half 2021 earnings released

Price target decreased to €2.13

Mauna Kea Technologies Receives U.S. FDA 510(k) Clearance of its Next-Generation Cellvizio® Platform Combined with a Fluorescent Contrast Agent

Consensus forecasts updated

Mauna Kea Technologies SA Provides Earnings Guidance for the Twelve Months Ending December 31, 2021

Mauna Kea Technologies Unveils Its Next-Generation Cellvizio® Platform

Full year 2020 earnings released

Mauna Kea Technologies: Cellvizio® Combined with Artificial Intelligence Outperforms Standard of Care for Pancreatic Cyst Diagnosis and Risk Stratification

What Is Mauna Kea Technologies SA's (EPA:MKEA) Share Price Doing?

Mauna Kea Technologies SA to Report Q2, 2021 Results on Jul 22, 2021

New 90-day high: €1.50

Mauna Kea Technologies Announces Board Changes

Telix Pharmaceuticals Limited and Mauna Kea Technologies Announces Exclusive Scientific and Clinical Research Collaboration

New 90-day high: €1.42

Mauna Kea Technologies (EPA:MKEA) Share Prices Have Dropped 70% In The Last Three Years

New 90-day high: €1.34

New 90-day low: €1.05

New 90-day low - €1.14

業績と収益の成長予測

アナリストによる今後の成長予測

一株当たり利益成長率予想

将来の株主資本利益率

成長企業の発掘